$0.31 EPS Expected for Genomic Health, Inc. (GHDX) This Quarter
Analysts forecast that Genomic Health, Inc. (NASDAQ:GHDX) will announce $0.31 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Genomic Health’s earnings. The lowest EPS estimate is $0.30 and the highest is $0.33. Genomic Health posted earnings of $0.08 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 287.5%. The company is expected to issue its next earnings report on Thursday, March 14th.
On average, analysts expect that Genomic Health will report full-year earnings of $1.06 per share for the current fiscal year, with EPS estimates ranging from $1.04 to $1.07. For the next fiscal year, analysts expect that the company will post earnings of $1.23 per share, with EPS estimates ranging from $1.04 to $1.55. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Genomic Health.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.28. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The business had revenue of $101.30 million for the quarter, compared to the consensus estimate of $94.27 million. During the same period last year, the firm earned ($0.06) earnings per share. The company’s quarterly revenue was up 23.2% on a year-over-year basis.
GHDX opened at $72.90 on Wednesday. Genomic Health has a 1-year low of $26.54 and a 1-year high of $92.18. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 92.07 and a beta of 0.40.
In other news, insider Steven Shak sold 5,500 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $63.05, for a total transaction of $346,775.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Frederic Pla sold 1,500 shares of the firm’s stock in a transaction on Monday, October 8th. The shares were sold at an average price of $65.43, for a total transaction of $98,145.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,635,985 shares of company stock worth $126,469,701 over the last 90 days. Insiders own 45.80% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Clearbridge Investments LLC purchased a new position in Genomic Health during the third quarter valued at $12,880,000. Vanguard Group Inc. grew its stake in Genomic Health by 18.6% during the third quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock valued at $151,109,000 after acquiring an additional 337,664 shares in the last quarter. Kepos Capital LP purchased a new position in Genomic Health during the third quarter valued at $1,864,000. Nordea Investment Management AB grew its stake in Genomic Health by 17.5% during the third quarter. Nordea Investment Management AB now owns 79,128 shares of the medical research company’s stock valued at $5,557,000 after acquiring an additional 11,776 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in Genomic Health by 38.0% during the third quarter. TIAA CREF Investment Management LLC now owns 242,839 shares of the medical research company’s stock valued at $17,052,000 after acquiring an additional 66,873 shares in the last quarter. 89.21% of the stock is owned by institutional investors.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Recommended Story: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.